Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

MindMed shares target cut on Q1 miss, Oppenheimer stays positive

EditorEmilio Ghigini
Published 2024-05-13, 08:06 a/m
MNMD
-

On Monday, Oppenheimer adjusted its outlook on MindMed (NASDAQ:MNMD) shares, a biotech company specializing in psychedelic-inspired therapies. The firm lowered its price target to $20 from the previous $29, while maintaining an Outperform rating.

MindMed recently disclosed its financial results for the first quarter of 2024, with earnings per share (EPS) falling short of expectations at a loss of $1.14. This was notably below Oppenheimer's estimate of a $0.46 loss per share and the consensus estimate of a $0.53 loss per share. The shortfall was largely attributed to costs associated with financing warrants.

Despite the earnings miss, Oppenheimer expressed optimism regarding MindMed's ongoing clinical programs. The company reported favorable outcomes from its Phase 2b trial, showing sustained improvements in the Hamilton Anxiety Rating Scale (HAM-A) at both the 4-week and 12-week marks.

These results support the continuation of MindMed's planned Phase 3 program, which is expected to begin in the second half of 2024 after an End of Phase 2 meeting scheduled for the second quarter of the year.

The Phase 2b success also paves the way for the exploration of additional uses for MM-120, MindMed's investigational therapeutic. The analyst noted the potential for MM-120 to treat depression, backed by secondary endpoint data from the Phase 2b trial that showed a significant reduction in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores.

Despite the reduction in the price target, the firm's reiteration of the Outperform rating indicates a belief in MindMed's long-term potential. The adjustment reflects current market conditions and the impact of recent dilution, as the company continues to navigate its path towards initiating its Phase 3 program.

InvestingPro Insights

As MindMed navigates its clinical and financial milestones, real-time data from InvestingPro provides a snapshot of the company's current market position. With a market capitalization of $665.54 million, MindMed's financial health is underscored by holding more cash than debt, which is a positive sign for investors. However, the company's P/E ratio stands at -3.06, reflecting the market's anticipation of future earnings and the challenges of reaching profitability, as analysts do not expect MindMed to be profitable this year. The adjusted P/E ratio for the last twelve months as of Q1 2024 further highlights this at -5.31.

InvestingPro Tips reveal that while MindMed has strong liquidity, with liquid assets surpassing short-term obligations, it suffers from weak gross profit margins. Additionally, MindMed has not been profitable over the last twelve months. Despite this, the company has experienced a high return over the last year, with a 202.61% price total return, and a notable 281.07% increase over the last six months, indicating significant investor interest and market momentum.

For readers looking to delve deeper into MindMed's financials and future prospects, additional InvestingPro Tips can provide further insights—there are 9 more tips available for MindMed, which can be found by visiting InvestingPro's MindMed page. To access these insights and more, use coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.